Cerebrolysin vs Colostrinin
A neutral, side-by-side comparison of two nootropic & cognitive peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
Cerebrolysin
Cerebrolysin is a brain-derived peptide mixture produced by controlled enzymatic breakdown of porcine brain proteins. Unlike synthetic peptides, it is a complex of ~25% low-molecular-weight neuropeptides and ~75% free amino acids, with the bioactive peptide fraction mimicking the endogenous neurotrophic factors BDNF, NGF, GDNF, and CNTF in their mechanisms. It has a 30+ year clinical history in Eastern Europe and Asia for stroke recovery, traumatic brain injury, Alzheimer's disease, and vascular dementia — with a substantial human trial database.
Full profileColostrinin
Proline-rich polypeptide complex isolated from ovine (sheep) colostrum. Originally researched as an Alzheimer's disease modulator, colostrinin has shown ability to stabilize cognitive function and reduce progression in mild-to-moderate Alzheimer's patients in double-blind trials. Also studied for immune modulation and anti-aging properties via cytokine balance normalization.
Full profile| Cerebrolysin | Colostrinin | |
|---|---|---|
| Category | Nootropic & Cognitive | Nootropic & Cognitive |
| Also known as | FPF 1070, EBEWE Cerebrolysin, Brain-derived peptide mixture | PRP (proline-rich polypeptide), ND, colostrum neuropeptide, CLN, ovine proline-rich polypeptide |
| Evidence | Research-stage | Research-stage |
| Dosing range | 5mL–30mL mL, Daily for 10–20 day courses (IV preferred in clinical use); SQ/IM for research access | 100mcg–400mcg mcg, sublingual, on a 3 days on / 3 days off cycle |
| Administration | Intravenous infusion (clinical standard — dilute in 100mL saline over 15–30 min), Intramuscular injection (research use — lower bioavailability), Subcutaneous injection (less common) | Sublingual tablet/drop |
| Key side effects | Injection site pain (IM route), Hyperthermia / fever (rare, higher doses), Agitation or anxiety (uncommon), Nausea | Generally well-tolerated, Mild GI discomfort, Rare hypersensitivity (relevant for dairy protein sensitivity), Mild fatigue (initial days) |
| Cited sources | 3 references | 2 references |
Key differences
- Administration: Cerebrolysin — Intravenous infusion (clinical standard — dilute in 100mL saline over 15–30 min), Intramuscular injection (research use — lower bioavailability), Subcutaneous injection (less common); Colostrinin — Sublingual tablet/drop.
- Dosing units differ: Cerebrolysin is dosed in mL, Colostrinin in mcg — they operate at different scales.
- Frequency: Cerebrolysin is typically Daily for 10–20 day courses (IV preferred in clinical use); SQ/IM for research access; Colostrinin is sublingual, on a 3 days on / 3 days off cycle.
- Research depth: this profile cites 3 sources for Cerebrolysin vs 2 for Colostrinin.
How each works
Cerebrolysin
Cerebrolysin's neuroprotective effects have been demonstrated in over 100 clinical trials, though most are from Eastern European and Asian centers with varying methodological quality. The CACTUS trial (N=256, multicenter) showed significant improvement in cognitive outcomes after ischemic stroke vs placebo. The ARTIST trials evaluated Cerebrolysin for Alzheimer's disease with mixed results. Meta-analyses of stroke and dementia trials generally support modest-to-moderate benefit. Mechanistically, the peptide fraction upregulates BDNF/NGF signaling, reduces excitotoxicity, inhibits caspase-3, and promotes synaptogenesis in animal and in vitro models.
Colostrinin
Colostrinin modulates dendritic cell maturation and shifts cytokine balance toward anti-inflammatory patterns (reduced IL-6, TNF-α; increased IL-10). In neurological models, it reduces amyloid-β aggregation, decreases oxidative stress, and upregulates NGF while modulating the HPA axis stress response. A Polish double-blind trial showed statistically significant cognitive stabilization in mild-to-moderate AD patients over 15 weeks.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.